We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Siemens and Sysmex Sign Global Hemostasis Supply Agreement

By LabMedica International staff writers
Posted on 10 Mar 2023

Sysmex Corporation (Kobe, Japan) and Siemens Healthcare Diagnostics Inc. (Siemens Healthineers, Erlangen, Germany) have signed a global OEM agreement on hemostasis products under which each company will supply the other with their products in the diagnostic field of hemostasis on an OEM basis.

Both Siemens and Sysmex provide hemostasis products used in testing for blood clotting disorders, preoperative bleeding risk management, and the monitoring of patients receiving anticoagulant therapy medications. Following their global agreement on distribution, sales, and services for hemostasis products signed in 1995, the two companies have since then developed a strong partnership and gone on to become one of the leading solution providers in the global hemostasis space. Over this period, the companies have further expanded their capabilities and gained strength by introducing new innovations in their product portfolios.

The demand for hemostasis has recently increased and become more diverse due to rising incidence of thrombotic diseases as a result of lifestyle diseases, development of new blood preparations, use in testing to predict COVID-19 severity, as well as higher demand for standardization, IT connectivity, and quality improvement in testing. Under the OEM agreement Sysmex and Siemens will individually offer laboratories even more compelling, effective hemostasis solutions globally, with the objective of addressing the changing testing environments of their customers and improving access to care in order to improve outcomes for patients across the world. Both the companies have further demonstrated their commitment to continue advancing hemostasis testing through their strengthened partnership.

The OEM agreement will allow both companies to distribute - globally and individually - under their respective brands their combined portfolio of hemostasis instruments and reagents, alongside their own wider portfolios of products and services. Going forward, the companies will each individually offer effective solutions to laboratories across the world that build on their respective strengths, based on one of the world’s most extensive hemostasis product portfolios achieved through the collaboration in order to meet diversifying client needs.

“Making our long-standing partnership with Siemens Healthineers even more sustainable, we remain committed to further enhance the value of hemostasis testing as a global leader,” said Kenji Tachibana, Member of the Managing Board and Senior Executive Officer, Senior Managing Director of Sysmex. “We will individually offer laboratories worldwide proprietary solutions with the benefit of our respective expertise and service portfolio, providing customers with access to the broadest set of solutions in the evolving market.”

"Siemens Healthineers and Sysmex have built a solid hemostasis partnership for more than 25 years," said Sharon Bracken, Head of Diagnostics for Siemens Healthineers. "The time has come to offer one of the world’s most extensive product portfolios achieved through mutual OEM supply to benefit customers and patients worldwide. With the OEM agreement, we will more effectively deliver quality and comprehensive hemostasis testing solutions to laboratories of all sizes across the world."

Related Links:
Siemens Healthineers
Sysmex Corporation 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.